Navigation Links
Rare medical phenomenon of systemic tumor disappearance following local radiation treatment reported in a patient with metastatic melanoma
Date:3/7/2012

March 8, 2012, NEW YORK A rarely seen phenomenon in cancer patients in which focused radiation to the site of one tumor is associated with the disappearance of metastatic tumors all over the body has been reported in a patient with melanoma treated with the immunotherapeutic agent ipilimumab (Yervoy). Researchers at Memorial Sloan Kettering Cancer Center shared their findings in a unique single-patient study, which could help shed light on the immune system's role in fighting cancer. Their observations suggest that the combination of ipilimumab and radiation may be a promising approach for the treatment of melanoma. The findings are published as a brief report in the March 8 issue of the New England Journal of Medicine. The work was done at Memorial Sloan Kettering's Ludwig Center for Cancer Immunotherapy.

The phenomenon reported by the researchers, known as the abscopal effect, occurs when localized radiation therapy delivered to a single tumor in a patient with advanced disease results in tumor disappearance outside of the irradiated area. Though the abscopal effect is extremely rare, it has been described in several cancers including melanoma, lymphoma, and kidney cancer.

"We are excited about these results, and what we have seen in this one patient proves the principle that adding radiation therapy to immunotherapy may be a promising combination approach to treatment for advanced cancer," explained senior author Jedd Wolchok, MD, PHD, a medical oncologist at Memorial Sloan Kettering Cancer Center with a joint appointment in the Sloan Kettering Institute's Immunology Program. "What we think is happening here is that the immune system's cancer-fighting response is turned up a notch with the addition of focused radiation," added Dr. Wolchok.

In the case study Dr. Wolchok and colleagues reported treating a patient with advanced melanoma using an immunotherapy called ipilimumab, recently approved by the US Food and Drug Administration. Over time the patient's melanoma slowly grew in the spleen, lymph nodes, and an area near the spine. When the disease progressed, the patient received localized radiation therapy to the melanoma tumor near the spine to help with pain relief. After the radiation treatment, the targeted tumor near the patient's spine shrank significantly. Unexpectedly, other areas where the melanoma had spread (the spleen and the lymph nodes) but that were not directly targeted by the radiation therapy also benefited, consistent with the abscopal effect. The patient continues to do well more than one year since receiving the radiation therapy.

Scientists are not certain how the abscopal effect works to eliminate cancer in patients. Studies in mice suggest that the effect may depend upon activation of the immune system. In the case study reported by Dr. Wolchok and colleagues at Memorial Sloan Kettering, changes in the patient's immune system were measured over the course of treatment. The team observed changes in tumor-directed antibody levels and immune cell populations that occurred at the time of the abscopal effect. These findings support the idea that radiation may help stimulate the immune system to fight cancer.

Ipilimumab is an immunotherapy that exploits the body's own immune system to attack cancer. It was approved by the FDA in March of 2011 and is the first drug ever to show an improvement in overall survival for patients with advanced melanoma. The therapy blocks a target called CTLA-4 and was developed by James Allison, PhD, Chair of the Sloan Kettering Institute's Immunology Program.

This patient's dramatic response provides new insight into how radiation may help activate the immune system to fight cancer and suggests novel therapeutic avenues to pursue. Clinical trials are under way now to validate the approach of combining radiation therapy with ipilimumab for the treatment of melanoma and prostate cancer.


'/>"/>

Contact: Jeanne D'Agostino
dagostij@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Many U.S. Families Struggle to Pay Medical Bills
2. Computerization May Not Curb Medical Tests, Costs
3. Springer launches 6 new medical review journals
4. Chemists mimic nature to design better medical tests
5. Medical debt keeps rising, new report shows
6. Handheld device for doing blood tests moves closer to medical use
7. Lsuhscs Gee helping address international medical education leadership void
8. Independent medical device review site Which Medical Device launches new Anaesthetics section
9. Scottish medical charity and international drug consortium form partnership
10. Oxford University Press and Medical Council on Alcohol announce long-term partnership
11. Georgetown University Medical Center licenses theranostic for development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: